Overview

  • Product name

    DMXAA (ASA404), VEGFR inhibitor
  • Description

    Vascular disrupting agent. VEGFR inhibitor.
  • Alternative names

    • ASA404
  • Biological description

    Vascular disrupting agent. VEGFR inhibitor. Potent type I interferon inducer. Increases vascular permeability and vascular endothelial apoptosis. Inhibits angiogenesis. Shows antiviral and antitumor effects in vivo.
  • Purity

    > 99%
  • CAS Number

    117570-53-3
  • Chemical structure

    Chemical Structure

Properties

Images

  • All lanes : Anti-Interferon beta antibody [EPR22186-266] (ab218229) at 1/1000 dilution

    Lane 1 : Untreated RAW 264.7 (mouse macrophage cell line transformed with Abelson murine leukemia virus) whole cell lysate
    Lane 2 : RAW 264.7 treated with 50 µg/ml DMXAA (ab143018) for 7 hours, then with 300 ng/ml Brefeldin A (BFA) added after 1 hour, whole cell lysate
    Lane 3 : Untreated RAW 264.7 whole cell lysate
    Lane 4 : RAW264.7 treated with 100 ng/ml lipopolysaccharide (LPS) for 6 hours, then with 300 ng/ml Brefeldin A (BFA) added after 3 hours, whole cell lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

    Observed band size: 24,26 kDa
    why is the actual band size different from the predicted?



    Exposure time : Lanes 1 and 2: 26 seconds; Lanes 3 and 4: 3 minutes.

    Blocking/Dilution buffer: 5% NFDM/TBST.

    Interferon beta can be induced to increase the expression by DMXAA or LPS in RAW264.7 cell (PMID: 23027866, PMID: 16020513).

    The doublet is likely due to isoforms (PMID: 7352261).

  • Interferon beta was immunoprecipitated from 0.35 mg of RAW 264.7 (mouse macrophage cell line transformed with Abelson murine leukemia virus) treated with 50μg/ml DMXAA (ab143018) for 1h, then together with 300ng/ml brefeldin A (BFA) for another 6h whole cell lysate with ab218229 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab218229 at 1/500 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/1000 dilution.

    Lane 1: RAW 264.7 (treated with DMXAA (ab143018)/BFA) whole cell lysate 10 μg (Input). 
    Lane 2: ab218229 IP in RAW 264.7 (treated with DMXAA (ab143018)/BFA) whole cell lysate. 
    Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab218229 in RAW 264.7 (treated with DMXAA (ab143018)/BFA) whole cell lysate.

    Blocking and dilution buffer: 5% NFDM/TBST.

References

This product has been referenced in:

  • Fridlender ZG  et al. Using macrophage activation to augment immunotherapy of established tumours. Br J Cancer 108:1288-97 (2013). Read more (PubMed: 23481183) »
  • Tijono SM  et al. Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Br J Cancer 108:1306-15 (2013). Read more (PubMed: 23481185) »
  • Tang CK  et al. The chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant. PLoS One 8:e60038 (2013). Read more (PubMed: 23555875) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab143018.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up